Progesterone receptor modulators for endometriosis.
Alexandros Loukas Grammatis, Tatjana Gibbons, Eberechi N Anucha et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness and safety of progesterone receptor modulators (PRMs) for managing endometriosis in women. The analysis included nine studies with 922 participants. Mifepristone showed potential benefits in reducing dysmenorrhoea (OR 0.07, 95% CI 0.03 to 0.15), but evidence quality was low to very low due to bias and imprecision.
Key findings
- Mifepristone may improve dysmenorrhoea (OR 0.07, 95% CI 0.03 to 0.15).
- Mifepristone may increase hot flushes (OR 28.79, 95% CI 3.93 to 210.73).
- Uncertainty remains regarding mifepristone's effect on dyspareunia (OR 0.23, 95% CI 0.10 to 0.51).
Why it matters
Understanding the effectiveness and safety of PRMs is crucial for clinicians managing endometriosis, as treatment options can significantly impact patient quality of life and symptom management.
What to keep in mind
The evidence was judged as low to very low certainty due to serious risk of bias, imprecision, and indirectness in outcomes.